CARGLUMIC Drug Patent Profile
✉ Email this page to a colleague
When do Carglumic patents expire, and what generic alternatives are available?
Carglumic is a drug marketed by Navinta Llc and Novitium Pharma and is included in two NDAs.
The generic ingredient in CARGLUMIC is carglumic acid. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the carglumic acid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Carglumic
A generic version of CARGLUMIC was approved as carglumic acid by NOVITIUM PHARMA on October 13th, 2021.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CARGLUMIC?
- What are the global sales for CARGLUMIC?
- What is Average Wholesale Price for CARGLUMIC?
Summary for CARGLUMIC
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Drug Prices: | Drug price information for CARGLUMIC |
| DailyMed Link: | CARGLUMIC at DailyMed |
US Patents and Regulatory Information for CARGLUMIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Navinta Llc | CARGLUMIC ACID | carglumic acid | TABLET, FOR SUSPENSION;ORAL | 213395-001 | Jun 22, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Novitium Pharma | CARGLUMIC ACID | carglumic acid | TABLET, FOR SUSPENSION;ORAL | 213729-001 | Oct 13, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
